Jump to Header Jump to Main Content Jump to Footer

trials found matching your search:


Displaying 20 of 271 Results
Age
Type
Conditions or Disease:

PhIII MK-5684 VS Alt AbirateroneAcetateOREnzalutamide Ptsw/mCRPC ThatProgressOnORAfter Tx w/One NHA

Arash Rezazadeh Kalebasty

  • OPEN TO ACCRUAL

PhIIIRandTriaEribulinW/GemcitabineVsStandCarTxMetaUrothelialCaRefracOrIneligAntiPD1/PDL1Therp

Nataliya Mar

  • OPEN TO ACCRUAL

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Zahra Pakbaz

  • OPEN TO ACCRUAL

Ph II Subcutan Amivantamab in Pts w/ Adv or Metastat SolidTumors EGFR-mutated Non-Small Cell Lung Ca

Misako Nagasaka

  • OPEN TO ACCRUAL

Ph I & Ph II Radium-223 Dichloride, M3814, & Avelumab in Adv Met Castrate-Resistant Prostate Cancer

Nataliya Mar

  • OPEN TO ACCRUAL

PhIII Odronextamab Comb w/CHOP vs Rituximab Comb w/CHOP in Prev Untrx Pts w/Diffuse Large Bcell Lymp

Elizabeth A Brem

  • OPEN TO ACCRUAL

Phase 2 Study of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis

Huawei Dong

  • OPEN TO ACCRUAL

A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in Subjects with PAH via OLE

Bassam Yaghmour

  • OPEN TO ACCRUAL

A Study Evaluating Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Bassam Yaghmour

  • OPEN TO ACCRUAL

Ph III IdecabtageneVicleucel w/Len VSLen Pts w/New DxMultiplMyelom Subopt RespAfter AutolStemCell Tr

Stefan Octavian Ciurea

  • OPEN TO ACCRUAL

PhI Ziftomenib Comb Tx of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Kiran Naqvi

  • OPEN TO ACCRUAL

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy, and Safety Study

Anand Ganesan

  • OPEN TO ACCRUAL

Evaluation of BE1116 (4F-PCC) in patients with traumatic injury

Jeffry Nahmias

  • OPEN TO ACCRUAL

A research study to look at how ziltivekimab works compared to placebo in people with heart

Dawn Lombardo

  • OPEN TO ACCRUAL

An observational study in patients with major bleedings in presence of Factor Xa inhibitor treatment

Alpesh Amin

  • OPEN TO ACCRUAL

PhIMeninInhibitorSNDX-5613ComboW/Daunorubicin&CytarabineNewDxPtsW/AcuteMyeloidLeukemia&NPM1

Kiran Naqvi

  • OPEN TO ACCRUAL

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Tahseen Mozaffar

  • OPEN TO ACCRUAL

Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b)

Judith Chung

  • OPEN TO ACCRUAL